22/02/2026
LiverWELL welcomes the WHO Executive Board’s draft resolution recognising steatotic liver disease (including MASLD) as a critical component of the global NCD agenda.
MASLD is a metabolic liver condition affecting 1 in 3 Australians and is closely connected to rising rates of type 2 diabetes, cardiovascular disease, and liver and other cancers.
This proposed resolution is an important step toward integrating liver health into national prevention, early detection, and equitable care.
We’re proud to continue driving national action through the MASLD Action Network and to work alongside government, clinicians, researchers, and communities to make liver health a public health priority in Australia.
Read more about the WHO resolution and why it matters: https://liverwell.org.au/liverwell-welcomes-who-draft-resolution/